A new Top Biopharma joined our ranks in 2011! With Genzyme swallowed up by Sanofi, Dendreon and its innovative prostate cancer therapy gained admission to the exclusive list.

As with the Top Pharma list, currency exchange flux makes it difficult to compare all of our Biopharmas, but U.S. dollar-reporting companies — Amgen, Baxter, Biogen, Allergan, Alexion and Dendreon — showed cumulative growth of 7% in 2011, combining for $29.0 billion in revenues. That’s up from 4% in 2010 (swapping Genzyme for Dendreon).

Note: a company qualifies as a “Biopharma” if it makes at least 50% of its drug revenues from selling biologics and vaccines. Small-molecule companies need not apply.

—Gil Y. Roth
Editor

Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks
The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)
Pipeline information compiled by Kristin Brooks
Revenue information compiled by Gil Roth

Photo of Avastin packaging courtesy of Roche

Top 10 Biopharma Companies
based on 2011 biopharma revenues

1	Roche	$37,110
2	Amgen	$15,582
3	Novo Nordisk	$12,400
4	Merck Serono	$8,243
5	Baxter BioScience	$6,053
6	Biogen Idec	$4,833
7	CSL Ltd.	$4,145
8	Allergan	$1,595
9	Alexion	$783
10	Dendreon	$214

2011 R&D Expenditures

1	Roche	$9,148
2	Amgen	$3,167
3	Novo Nordisk	$1,799
4	Merck Serono	$1,706
5	Biogen Idec	$1,220
6	Baxter	$946
7	Allergan	$903
8	CSL Ltd.	$322
9	Alexion Pharma	$137
10	Dendreon	$74

Note: In all Top Company profiles, dollar amounts are in millions.